Profile
International Journal of Radiology & Medical Imaging Volume 1 (2015), Article ID 1:IJRMI-102, 3 pages
https://doi.org/10.15344/2456-446X/2015/102
Mini Review
Use of 99mTc-labelled Anti-TNF Monoclonal Antibodies to Assess Patients Affected by Inflammatory Arthropathies

Fulvia Ceccarelli1, Carlo Perricone1, Filippo Galli2, Guido Valesini1 and Fabrizio Conti1*

1Rheumatology, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Roma, Italy
2Nuclear Medicine Unit,Faculty of Medicine and Psychology,Department of Medical-Surgical Sciences and Translational Medicine, "Sapienza" University,Ospedale S. Andrea, Via di Grottarossa 1035; 00189 Rome, Italy
Dr. Fabrizio Conti, Rheumatology, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Roma, Italy; E-mail: fabrizio.conti@uniroma1.it
20 March 2015; 01 July 2015; 03 July 2015
Ceccarelli F, Perricone C, Galli F, Valesini G, Conti F (2015) Use of 99mTc-labelled anti-TNF Monoclonal Antibodies to Assess Patients Affected by Inflammatory Arthropathies. Int J Radiol Med Imag 1: 102. doi: https://doi.org/10.15344/2456-446X/2015/102

References

  1. Chianelli M, D'Alessandria C, Conti F, Priori R, Valesini G, et al. (2006) New radiopharmaceuticals for imaging rheumatoid arthritis. Q J Nucl Med Mol Imaging 50: 217-225. View
  2. Barrera P, Oyen WJ, Boerman OC, van Riel PL (2003) Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 62: 825-828. View
  3. D’Alessandria C, Malviya G, Viscido A, Aratari A, Maccioni Fet al. (2007) Use of a 99m-Technetium labelled anti-TNFa monoclonal antibody in Crohn’s Disease: in vitro and in vivo studies.Q J Nucl Med Mol Imaging 51:1-9.
  4. Conti F, Ceccarelli F, Massaro L, Cipriano E, Di Franco M, et al. (2013) Biological therapies in rheumatic diseases. Clin Ter 164: e413-428. View
  5. Sedger LM, McDermott MF (2014) TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev 25: 453-472. View
  6. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, et al. (2007) Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 7: 35-41. View
  7. Conti F, Priori R, Chimenti MS, Coari G, Annovazzi A, et al. (2005) Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab. Arthritis Rheum 52: 1224-1226. View
  8. Conti F, Malviya G, Ceccarelli F, Priori R, Iagnocco A, et al. (2012) Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis. Eur J Nucl Med Mol Imaging 39: 1339-1347. View
  9. Adalimumab (Humira). European Public Assessment Report Scientific Discussion.
  10. Malviya G, D’Alessandria C, Lanzolla T, Lenza A, Conti F, Valesini G, et al. (2008) 99mTechnetium labelled anti-TNF-α antibodies for the therapy decision-making and follow-up of patients with rheumatoid arthritis. Q J Nucl Med Mol Imaging 52(Suppl 1(2)):13–14.